主要文件

查看所有文档

Y0000401

Pimobendan for system suitability

Name: Pimobendan for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

Pimobendan, 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₉H₁₈N₄O₂

化学文摘社编号:

74150-27-9

分子量:

334.37

NACRES:

NA.24

PubChem Substance ID:

329830936

UNSPSC Code:

41116107

MDL number:

MFCD00761648

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

pimobendan

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C(C1=CC=C(NC(C2=CC=C(OC)C=C2)=N3)C3=C1)=NN4)CC4=O

InChI

1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)

InChI key

GLBJJMFZWDBELO-UHFFFAOYSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Pimobendan for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

GHS06

signalword

Danger

hcodes

H301

pcodes

P264 - P270 - P301 + P310 + P330 - P405 - P501

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

The effect of pimobendan on left atrial pressure in dogs with mitral valve regurgitation.

S Suzuki et al.

Journal of veterinary internal medicine, 25(6), 1328-1333 (2011-11-19)

The effects of pimobendan on left atrial pressure (LAP) in dogs with mitral valve disease (MR) have not been documented in a quantitative manner. The objective was to document and study the short-term effects of pimobendan on LAP and echocardiographic

Use of pimobendan in 170 cats (2006-2010).

John M Macgregor et al.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 13(4), 251-260 (2011-10-28)

To describe the therapeutic use of pimobendan in cats, describe the patient population to which it was administered, document potential side effects and report the clinical course following administration of pimobendan in conjunction with standard heart failure therapy. It is

Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.

K J Atkinson et al.

Journal of veterinary internal medicine, 23(6), 1190-1196 (2009-09-29)

Pimobendan is a positive inotrope and vasodilator that may be useful in the treatment of pulmonary hypertension (PHT) secondary to degenerative mitral valve disease. Pimobendan decreases the severity of PHT measured echocardiographically and improves quality-of-life scores. Changes in N-terminal probrain

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0000401	04061833803400